The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution

Article metrics

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Nowell PC . The clonal evolution of tumor cell populations. Science 1976; 194: 23–28.

  2. 2

    Hallek M, Bergsagel PL, Anderson KC . Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91: 3–21.

  3. 3

    López-Corral L, Sarasquete ME, Beà S, García-Sanz R, Mateos MV, Corchete LA et al. SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status. Leukemia 2012; 26: 2521–2529.

  4. 4

    Puig N, Sarasquete ME, Balanzategui A, Martínez J, Paiva B, García H et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia 2014; 28: 391–397.

  5. 5

    Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012; 120: 1067–1076.

  6. 6

    Van Dongen JJ, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2013; 17: 2257–2317.

  7. 7

    Bakkus MH, Heirman C, Van Riet I, Van Camp B, Thielemens K . Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 1992; 80: 2326–2335.

  8. 8

    Zojer N, Ludwig H, Fiegl M, Stevenson FK, Sahota SS . Patterns of somatic mutations in VH genes reveal pathways of clonal transformation from MGUS to multiple myeloma. Blood 2003; 101: 4137–4139.

  9. 9

    Ralph QM, Brisco MJ, Joshua DE, Brown R, Gibson J, Morley AA . Advancement of multiple myeloma from diagnosis through plateau phase to progression does not involve a new B-cell clone: evidence from the Ig heavy chain gene. Blood 1993; 82: 202–206.

  10. 10

    Kühnemund A, Liebisch P, Bauchmüller K, zur Hausen A, Veelken H, Wäsch R et al. ‘Light chain escape-multiple myeloma’- an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. J Cancer Res Clin Oncol 2009; 135: 477–484.

  11. 11

    Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, de la Rubia J et al. Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 2012; 120: 1589–1596.

  12. 12

    Sarasquete ME, García-Sanz R, González D, Martínez J, Mateo G, Martínez P et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica 2005; 90: 1365–1372.

  13. 13

    Beishuizen A, Hählen K, Hagemeijer A et al. Multiple rearranged immunoglobulin genes in childhood acute lymphoblastic leukemia of precursor B cell origin. Leukemia 1991; 5: 657–667.

  14. 14

    Langlands K, Craig JI, Anthony RS, Parker AC . Clonal selection in acute lymphoblastic leukaemia demonstrated by polymerase chain reaction analysis of immunoglobulin heavy chain and T-cell receptor delta chain rearrangements. Leukemia 1993; 7: 1066–1070.

  15. 15

    Martínez-Lopez J, Lahuerta JJ, Pepin F, González M, Barrio S, Ayala R et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 2014; 123: 3073–3079.

Download references


This work is partially supported by grants PS09/01450 and PI12/02311 from the Spanish ‘Instituto de Salud Carlos III (ISCIII)’, grants RD12/0036/0069 & 0058 from ‘Red Temática de Investigación Cooperativa en Cáncer (RTICC), Spanish Ministry of Economy and Competitiveness’ & European Regional Development Fund (ERDF) ‘Una manera de hacer Europa’, grant number HUS412A12-1 from the ‘Consejería de Educación de la Junta de Castilla y León’, and grant GCB-120981SAN from the ‘Asociación Española Contra el Cáncer (AECC)’. We thank Alicia Antón, Montserrat Hernández Ruano and Rebeca Maldonado for technical support.

Author information

Correspondence to M González-Díaz.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Puig, N., Conde, I., Jiménez, C. et al. The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution. Leukemia 29, 1435–1437 (2015) doi:10.1038/leu.2015.7

Download citation

Further reading